Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of Desmodium styracifolium

Li, Xue; Chen, Chao; Ding, Nan; Zhang, Tianjiao; Zheng, Peiyong; Yang, Ming

doi:10.3389/fphar.2022.1073535

Cited by 4 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phytochemical studies have revealed that flavonoids and phenolic acids constitute crucial active constituents, contributing significantly to the pharmacological efficacy (Sun et al, 2013). Schaftoside emerges as one of the primary active constituents, and to a certain degree, it is regarded as the representative compound of the total flavonoids of Desmodium styracifolium (TFDS) (Li et al, 2022). Pharmacological studies have demonstrated that schaftoside possesses a diverse array of pharmacological activities.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic and oral bioavailability study of schaftoside in rats

Lin,

Wang,

et al. 2024

Biomedical Chromatography

View full text Add to dashboard Cite

A simple and sensitive LC–tandem mass spectrometry method was established and validated for the determination of schaftoside in rat plasma. After prepared by protein precipitation with acetonitrile, schaftoside and internal standard were separated on a Waters HSS T3 column using acetonitrile containing 0.1% formic acid and 0.1% formic acid in water as the mobile phase by gradient elution. The method showed excellent linearity over the range of 0.5–500 ng/mL with acceptable intra‐ and inter‐day precision, accuracy, matrix effect, and recovery. The stability assay indicated that schaftoside was stable during the sample acquisition, preparation, and storage. The method was applied to a pharmacokinetic study of schaftoside in rats. The result suggested that after intravenous administration at a dose of 1 mg/kg, schaftoside was quickly eliminated from the plasma with an elimination half‐life of 0.58 h. After oral administration at doses of 5, 10, and 20 mg/kg, schaftoside was quickly absorbed into the plasma and reached the peak concentration (Cmax) of 45.1–104.99 ng/mL at 0.67–1.17 h. The increase of exposure (area under the curve) was linear with the increase of dose. The oral bioavailability was 0.42%–0.71% in the range of 5–20 mg/kg.

show abstract

Section: Introductionmentioning

confidence: 99%